Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
ATEMPT 2.0: Adjuvant T-DM1 vs TH
for
Breast Cancer, HER2-positive Breast Cancer
Location: Nashville TN, Columbus OH, Chicago IL, Pittsburgh PA,
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT04893109
Phase2, Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
for
Metastatic Colorectal Cancer
Location: Nashville TN, Pikeville KY, Chicago IL, Durham NC,
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
for
NSCLC Stage IV
Location: Nashville TN, Atlanta GA, Cincinnati OH, St Louis MO,
Sponsor: ImmunityBio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06745908
Phase3, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Get alerts for new trials in your area by subscribing now
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
for
HER2-positive Advanced Solid Tumor
Location: Nashville TN, Newnan GA, Saint Louis MO, Chicago IL,
Sponsor: DualityBio Inc.
Sex: All
Age: 18+
Code: NCT05150691
Phase1, Phase2, Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
for
Triple Negative Breast Cancer
Location: Nashville TN, Germantown TN, Atlanta GA, St Louis MO,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT06926920
Phase1, Phase2, Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Atlanta GA, Chapel Hill NC, Fairfax VA,
Sponsor: Genmab
Sex: All
Age: 18+
Code: NCT07288177
Phase2, Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Location: Nashville TN, Atlanta GA, Columbus OH, Chicago IL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06876662
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
for
Breast Neoplasms
Location: Nashville TN, Lexington KY, Cincinnati OH, Charlotte NC,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07060807
Phase3, Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)